To determine if the efficacy of the combination between RT and MRTX1257 relies upon the presence of KRASG12C mutation in CT26 tumors, we performed a similar tumor growth experiment in BALB/c mice bearing CT26 WT tumors (Fig. 4A). The gene discussed is DDX53; the disease is neoplasm.